SCHEDULE 13G/A: Goldman Sachs Discloses 2.4% Passive Stake in Silexion Therapeutics
Beneficial Ownership Statement (Schedule 13G Amendment)
The Goldman Sachs Group, Inc. and its affiliate Goldman Sachs & Co. LLC have reported a 2.4% beneficial ownership stake in Silexion Therapeutics Corp. as of March 31, 2025.
Summary
- The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC jointly reported beneficial ownership of 211,945 ordinary shares of Silexion Therapeutics Corp.
- This ownership represents 2.4% of Silexion Therapeutics Corp.'s outstanding ordinary shares.
- The filing is an Amendment No. 1 to a Schedule 13G, indicating a previous filing existed.
- The reporting persons hold shared voting power over 211,945 shares and shared dispositive power over 211,945 shares.
- The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual regulatory filing (Schedule 13G) disclosing beneficial ownership. It contains no qualitative information, financial performance data, or strategic updates that would influence sentiment positively or negatively. The sentiment is neutral as it simply reports a passive stake.
Future Outlook
NA
Industry Context
This filing indicates a passive investment by a major financial institution, Goldman Sachs, in a biotechnology or pharmaceutical company, Silexion Therapeutics Corp. Such investments are common for large asset managers and do not necessarily imply strategic intent beyond portfolio diversification or market exposure.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's passive stake, which can be viewed as a vote of confidence or simply a portfolio allocation.
Key Dates
| Date | Description |
|---|---|
| 07/29/2024 | Effective date of Power of Attorney for The Goldman Sachs Group, Inc. |
| 10/01/2024 | Effective date of Power of Attorney for Goldman Sachs & Co. LLC. |
| 03/31/2025 | Date of event which requires filing of this statement (reporting date for ownership). |
| 04/02/2025 | Date of signing and filing of the Schedule 13G Amendment No. 1. |
| 07/29/2025 | Expiration date of Power of Attorney for The Goldman Sachs Group, Inc. |
| 10/01/2025 | Expiration date of Power of Attorney for Goldman Sachs & Co. LLC. |
Keywords
Silexion Therapeutics Corp., Goldman Sachs Group Inc., Goldman Sachs & Co. LLC, Schedule 13G, Beneficial Ownership, Ordinary Shares, SEC Filing, Investment, Passive Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.